Henderson Opportunities Share Discussion Threads

[holdontight] 23/11/2005 22:53

Header and holdings updated, 23/11/05. Next update at end of Feb 06.

10 Main stocks on watchlist :

1. ITM
2. ADA
3. POL
4. MTT
5. TMC
6. DAN
7. CSB
8. DEBT
9. RDG
10. CYH

[holdontight] 23/11/2005 22:30

AVM Drilling Results Update: (apparently these are very good!).....also director buying RNS yesterday!!

RNS Number:3944U
Avocet Mining PLC
21 November 2005


Avocet Mining PLC
7th Floor 9 Berkeley Street
London W1J 8DW
Tel [phone]
Fax [phone]
E-mail [e-mail]
www.avocet.co.uk


News Release

For Immediate Release
Date 21 November 2005

UPDATE AND DRILL RESULTS FROM THE IDENBURG JOINT VENTURE, INDONESIA

Avocet Mining PLC ("the Company") is pleased to announce an exploration update
including drilling results from an initial 10 hole diamond drilling campaign at
the Idenburg JV in Indonesia. The Company has the right to earn a 51% interest
in an Indonesian company, PT Iriana Mutiara Idenburg ("PT IMI"), by expending
US$2.5 million prior to December 2006. PT IMI holds a 6th generation Contract of
Work ("CoW") with the Government of the Republic of Indonesia. The Company has
already spent US$1.35 million on work that will count towards the earn-in
expenditure.

The CoW includes exploration and mining rights over 108,600 hectares
(approximately 420 square miles) in the Idenburg area of Papua Province
(formally Irian Jaya) on the island of New Guinea. New Guinea hosts some of the
world's largest gold deposits, including multi-million ounce reserves at the
Grasberg and Porgera mines.

The Company's objective for 2006 is to drill a number of targets, in the
Sua-Afley district, with the potential of hosting ore zones similar to that
already identified by the initial 10 hole scout drilling programme at Sua,
discussed below. Infill drilling will then follow to outline a resource base.

Exploration this year has been conducted within an E-W elongate 6 x 3km area
from Afley prospect in the west to the Sua prospect in the east where the
Company had identified several zones of high-grade mineralisation within a 400m
strike length and 500m width. Since June 2005 the focus has been on completing
concurrent programs of first-pass drilling at Sua and systematic ridge and spur
soil sampling over the Kuaplu Ridge dividing the Afley and Sua prospects. The
first-pass 10 hole diamond drilling program totalling 1,373m, with 100m spacing,
was completed at the Sua prospect to target down dip extensions of gold-bearing
quartz-pyrite veins mapped in surface trench and creek exposures. Half drillcore
samples were analysed geochemically by PT. Superintending Company of Indonesia
(Sucofindo) in Timika, an internationally recognised laboratory that services
international mining companies throughout Indonesia. Mineralised intercepts
occurred in all holes except KSD009. Best results from fresh vein material were
7.5m at 16.0 g/t Au from 21m in hole KSD002, 3.0m at 35.0 g/t Au from 107m in
hole KSD008 and 3m at 17.7 g/t Au from 55m in hole KSD010. Stringer vein
mineralisation in near surface oxidised zones was best represented in hole
KSD001 with 13m at 2.86 g/t Au from surface and in hole KSD010 with 16m at 2.20
g/t Au also from surface. Full drill results are listed in Table 1.

More recently a total of 620 ridge and spur soil samples were collected
primarily testing the Kuaplu Ridge area between Afley and Sua prospects. A
distinct soil anomaly was identified on the western flank of the main Kuaplu
Ridge where 5 adjacent soil samples recorded gold values ranging from 1.43 g/t
Au to 3.55 g/t Au over a 125m segment of the ridge. Trenching is underway to
elucidate the significance of this soil anomaly.

A recent field review of the Sikrima zone in the Afley prospect noted high-grade
gold vein material confined to small boudins with dimensions less than 2 x 5m.
Outcropping vein segments returned assays including 3m at 13.0 g/t Au, 2m at
12.1 g/t Au, 1m at 81.7 g/t Au, 0.30m at 166 g/t Au, 0.30m at 102 g/t Au, and
grab samples assaying 210 g/t Au and 71.8 g/t Au. The surface distribution of
the mineralised boudin exposures appear to be within a 100m segment of a
potential 2-3km NE trending structural envelope that extends up to Silia Creek.
Previous regional work in Silia Creek collected rock float assaying 260 g/t Au
and 49.8 g/t Au. Recent prospecting of inferred extensions 1km to the NE of
Sikrima located additional outcropping vein material at three locations on Silia
Ridge to the NW of Silia Creek and outside the ridge and spur soil tested area.
A total of 12 rock chips were collected with best rock chip results from each
separate location of 2m at 11.3 g/t Au and 0.55% Cu, and outcrops of 8.47 g/t Au
and 19.6 g/t Au. A program of tape and compass controlled mapping and sampling
along with collection of ridge and spur samples is currently underway over Silia
Ridge.

The Bermol and Mafi prospects continue to represent the next generation of
targets within the CoW. Both lie on an under-explored, fifteen-kilometre long
structure. Previous channel sampling at Bermol returned 8m at 5.81 g/t Au, 6m at
8.42 g/t Au, 8m at 5.78 g/t Au and 4m at 19.4 g/t Au. Scout drilling at Mafi
intersected up to 12.6m at 8.00 g/t Au.

Avocet is a mining company listed on the AIM market of the London Stock
Exchange. The Company's principal activities are gold mining and exploration in
Malaysia (as 100% owner of the Penjom mine, the country's largest gold
producer), Tajikistan (as 75% owner and operator of the Zeravshan Gold Company,
Tajikistan's principal gold mine), and Indonesia (as 80% owner of the North
Lanut gold mine in North Sulawesi).

Table 1
--------------------------------------------------------------------------------
Hole From To Length Grade
ID (m) (m) (m) (g/t Au)
--------------------------------------------------------------------------------
KSD001 0 13 13 2.86
and 23 26 3 2.87
and 33 38 5 1.69
and 41 45 4 5.96
incl. 44 45 1 18.0
and 65 69 4 1.93
KSD002 21 27.2 6.2 18.5
incl. 25.6 27.2 1.6 52.5
and 28 28.5 0.5 10.5
and 79 80 1 17.0
KSD003 74 75 1 3.08
KSD004 41 42 1 1.76
and 44 46 2 1.51
and 123 124 1 33.8
KSD005 80 89 9 4.00
incl. 88 89 1 25.8
and 95 97 2 2.16
and 112 113 1 1.21
and 118 119 1 1.96
KSD006 20 21 1 1.30
KSD007 32 33 1 1.26
and 56 57 1 1.25
and 66 67 1 1.71
and 71 72 1 5.25
KSD008 70 71 1 3.18
and 107 110 3 35.0
and 111 112 1 3.77
KSD010 0 16 16 2.20
and 28 30 2 1.87
and 44 48 4 4.41
incl. 44 45 1 13.8
and 55 58 3 17.7
incl. 55 57 2 24.2
and 64 67 3 2.19
and 74 75 1 1.39
--------------------------------------------------------------------------------

________________________________________________________________________________

For further information please contact:
Avocet Mining PLC
John Catchpole (Chief Executive)
Jonathan Henry (Finance Director)
020 7907 9000


This information is provided by RNS
The company news service from the London Stock Exchange
END
DRLPKFKPOBDDNDD

[holdontight] 23/11/2005 21:44

NLR upgraded :

Wednesday, November 23, 2005 6:08:37 AM ET
Dow Jones Newswires

0947 GMT [Dow Jones] Numis lifts Neteller (NLR.LN) target price to 1050p from 1000p. Ups 06 pretax estimate by 4% to $151.7M with EPS of 111.1 cents to reflect a lower operating cost assumption and lower bad debt charge assumption. Keeps 05 pretax profit at $96.7M but cuts EPS to 71.5 cents from 72.6 cents. "An enviable track record and expertise in securely processing licensed online gaming transactions worldwide, a strong management team, 33% compound forecast EPS growth over the next three years and a compelling valuation underline the group's attractions. Buy rating. Shares +1.7% at 667p. (DWE)

Source:

[holdontight] 23/11/2005 13:45

ALEA tp reduced.....95p target price now under review

ALEA (112p) - REDUCE, TP 95p (Under Review) - Sale of Renewal Rights
> (Last different recommendation SELL 7 November 2005)
> Sale of Renewal Rights: Alea has announced the sale of the renewal rights to around half of its Alea Alternative Risk (AAR) business to AmTrust. AAR has been the best performing part of the group in recent years and we expect the business to account for about 35% of group gross premiums written in 2005.
> Consideration: AmTrust is paying an immediate cash advance of $12m, with the potential for additional consideration based on 3% of gross premiums written in the next five years. Although there is a theoretical cap of $75m, Alea expects to receive a total consideration in the range of $20m to $40m (including the $12m advance), which we estimate equates to a range of 4p to 9p after tax. The group also estimates annualised savings of approximately $6m from the transaction.
> Recommendation: Despite this transaction the uncertainty regarding Alea's future remains. The remainder of AAR's business has been placed in run-off and we expect this to be the most likely scenario for the group's other less attractive businesses. We continue to believe that the appetite of potential buyers is likely to have been reduced by more attractive opportunities arising out of recent hurricane losses. In our view the run-off scenario would be negative for shareholders, mainly due to the time it would take to extinguish the liabilities of Alea's longer tail liabilities. We will review our target price to reflect the sale proceeds from this deal, but with an estimate of losses from hurricane Wilma still to be announced, the net benefit may only be modest and we therefore remain cautious.

[holdontight] 21/11/2005 19:29

Encouraging movement today on GMC, PST, DAN and NLR.

AVM is like a desparate man with a stiffy in a brothel!!

[arpy_is_back] 20/11/2005 11:04

I'll join you on the gold.

[holdontight] 18/11/2005 20:19

Closed PIC long.....too early in all liklihood but I need to show some gains this week after ITH disaster. May look at from investment rather than trading perspective next week, so long as price does not run away with itself!

Also closed DAN long but as with PIC, may revisit from investment perspective.

Looking to short gold, but its showing too much strength at mo - I can however see a retrace to $464 still, which is 20 points I'd like.

[holdontight] 18/11/2005 13:20

PIC : moving up well....CSCO buying Scientific Atlanta....puts PIC in place....US investors should now pile in, IMO.

[holdontight] 17/11/2005 23:21

DAN : Superb results today and PE now well below where it should be....fair price 28-32p.


LONDON (AFX) - Daniel Stewart Securities PLC said its pretax profit jumped
146 pct in the six months to end September and that it continued to trade well
in the first six weeks of the second half.
First-half pretax profit surged to a record 2.20 mln stg from 892,597 stg in
the year-earlier period as group turnover soared 153 pct to 5.25 mln from a
restated 2.07 mln.
Turnover and cost of sales were both restated to reflect the net
margin achieved from the company's share trading activities, it said. The
adjustment had no effect upon profit.
It said it is confident for the remainder of the financial year.
[e-mail]
jc

[holdontight] 17/11/2005 23:18

PIC ridiculously under valued. Added more today.

[holdontight] 17/11/2005 23:12

ELA news........tomorrow will be interesting!!! 5% spIke after hours in US!!!

FROM ELAN WEBSITE.

17 November 2005
Biogen Idec and Elan Announce FDA Acceptance of Supplemental Biologics License Application and Priority Review Designation for TYSABRI(R) in Multiple Sclerosis
CAMBRIDGE, Mass. and DUBLIN, Ireland--(BUSINESS WIRE)--Nov. 17, 2005--Biogen Idec (NASDAQ: BIIB - News) and Elan Corporation, plc (NYSE: ELN - News) announced today that the supplemental Biologics License Application (sBLA) for TYSABRI® (natalizumab) for the treatment of multiple sclerosis (MS) has been accepted and designated for Priority Review by the U.S. Food and Drug Administration (FDA).
The FDA grants Priority Review status to products that are considered to be potentially significant therapeutic advancements over existing therapies that address an unmet medical need. Based on the FDA's designation of Priority Review for TYSABRI in MS, the companies anticipate action by the Agency approximately six months from the submission date, rather than 10 months for a standard review. On September 26, 2005, the companies announced they had submitted the sBLA for the market re-entry of TYSABRI for MS and requested Priority Review.

The sBLA for TYSABRI in MS includes:


final two-year data from the Phase III AFFIRM monotherapy trial and SENTINEL add-on trial with AVONEX® (Interferon beta-1a) in MS;
integrated safety assessment of patients treated with TYSABRI in clinical trials; and
revised label and risk management plan.
"We are pleased that TYSABRI has received Priority Review designation, which we believe, reflects the unmet need in MS," said Burt Adelman, MD, executive vice president, Development, Biogen Idec. "We look forward to working with the FDA throughout the review process and are hopeful that we will be able to bring TYSABRI back to people living with MS."

"We believe that the acceptance of the sBLA for Priority Review is another step in our ongoing commitment to provide TYSABRI as a treatment option for MS patients in need," said Lars Ekman, MD, executive vice president and president, Research & Development, Elan. "We will continue to work closely with the FDA as they review the filing so that TYSABRI can be made available with an appropriate benefit-risk profile."

On February 28, 2005, Biogen Idec and Elan announced that they voluntarily suspended TYSABRI from the U.S. market and all ongoing clinical trials based on reports of progressive multifocal leukoencephalopathy (PML), a rare and potentially fatal, demyelinating disease of the central nervous system. Biogen Idec and Elan recently completed a comprehensive safety evaluation of more than 3,000 TYSABRI patients in collaboration with leading experts in PML and neurology. The results of the safety evaluation yielded no new confirmed cases of PML beyond the three previously reported.

About Biogen Idec

Biogen Idec creates new standards of care in oncology, neurology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit

Safe Harbor/Forward Looking Statements

This press release contains forward-looking statements regarding the regulatory path forward of TYSABRI. The regulatory path forward of TYSABRI is subject to a number of risks and uncertainties. Factors which could cause actual results to differ materially from the companies current expectations include the risk that concerns may arise from additional data or analysis or that the companies may encounter other unexpected delays or hurdles. There is no assurance that the companies will be able to resume marketing and sales of TYSABRI. Drug development and commercialization involves a high degree of risk. For more detailed information on the risks and uncertainties associated with the companies' drug development and other activities, see the periodic reports that Biogen Idec and Elan have filed with the Securities and Exchange Commission. The companies assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

[holdontight] 17/11/2005 14:05

You are welcome.

Closed EMG short yesterday, thank goodness.

Gold had a flyer, may now have a rest/retrace. Closed all gold longs today.

[arpy_is_back] 17/11/2005 14:03

thanks for that.

[holdontight] 17/11/2005 11:21

Note just out from Dawnay,Day Townsly:

Indigestion post the 29% placing gives further buying opportunity
Not surprisingly the share-price is reflecting the recent placing of 29% of NETeller's entire issued share capital. The recent mixed news from the quoted gambling companies has also served to depress the entire gaming sector.

The significant recent growth in user numbers will benefit the group in the future with the majority of gambling arising from clients signed in the last year and only a small tail from older members. Thus the significant addition of numbers this year gives us some assurance of future healthy growth. Even if the US/European membership growth flattens we believe NETeller's expansion in to the Far East will ensure strong growth next year.

Investors should note the valuations, especially the PER as we approach the year end. On a soon to be prospective PE below 10, NETeller is a bargain that should not be ignored.
Target price 960p, BUY.

[holdontight] 15/11/2005 12:42

Yes

Went long ELA and PIC yesterday. Went short EMG yesterday.

Closed AZM, CSR and PUB longs today, for small profit.

[arpy_is_back] 14/11/2005 09:36

holdontight

do you trade december gold ?

[holdontight] 13/11/2005 19:47

On back of latest results, I have added NCH to watch list.

[holdontight] 13/11/2005 11:12

NVU added to watch list.

[holdontight] 11/11/2005 22:43

FIB added to watch list.

[holdontight] 11/11/2005 22:38

All gold longs now sold....hoping for re-entry c$464.

[holdontight] 11/11/2005 19:35

RED added to watch list....signs of activity last 2 days.

Sold some Gold longs today, but not all. Looking to re-enter at $464, where there seems to be a gap needs filling.

[holdontight] 11/11/2005 14:23

Bought DAN today at 15.75p ahead of results next week.

[holdontight] 10/11/2005 15:54

CSR long closed at 795. MCGN long closed at 72.
Gold longs doing very well - I added last night.

Added SPW long and also CW. (again!).

[holdontight] 10/11/2005 10:13

Arpy - my successful trades tend to be in stocks I have followed for a while. GSK isn't one of these. I'll have a look at it when I get some spare time, but I do know that someone on the sbet thread follows them,,,,supermum I think!

CSR flying!!!!

[arpy_is_back] 10/11/2005 00:04

would appreciate your thoughts on gsk

thanks